Ultragenyx Pharmaceutical Inc. RARE

NAS: RARE | ISIN: US90400D1081   3/07/2025
39,91 USD (+1,14%)
(+1,14%)   3/07/2025

6 januari 2025 · European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) · Persbericht

28 mei 2024 · Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH) · Persbericht

4 januari 2024 · Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) · Persbericht

18 december 2023 · Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) · Persbericht

3 maart 2021 · Ultragenyx to Present at Barclays Global Healthcare Conference · Persbericht

17 februari 2021 · Ultragenyx to Present at Upcoming Investor Conferences · Persbericht

11 februari 2021 · Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update · Persbericht

4 februari 2021 · Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update · Persbericht

21 januari 2021 · Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease · Persbericht

8 januari 2021 · Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies · Persbericht

5 januari 2021 · Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference · Persbericht

Mijn selecties